发明名称 |
Adhesive hydrogels for ophthalmic drug delivery |
摘要 |
Some aspects of this disclosure relate to a method of treating an opthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent. |
申请公布号 |
US9125807(B2) |
申请公布日期 |
2015.09.08 |
申请号 |
US200711825848 |
申请日期 |
2007.07.09 |
申请人 |
Incept LLC |
发明人 |
Sawhney Amarpreet S.;Ransone, II William H. |
分类号 |
A61K47/10;A61K9/00;A61K31/196;A61K31/405;A61K31/4422;A61K31/4458;A61K31/496;A61K31/573;A61K31/58 |
主分类号 |
A61K47/10 |
代理机构 |
Dardi & Herbert, PLLC |
代理人 |
Dardi & Herbert, PLLC ;Herbert Curtis B. |
主权项 |
1. A method of treating an opthalmic disease affecting an eye of a patient comprising forming, a biodegradable covalently-crosslinked hydrogel in situ at a topical site, the hydrogel comprising a therapeutic agent that is released to treat the ophthalmic disease over a period of time that is at least about two days, wherein the hydrogel is adherent only to the site and the hydrogel is low-swelling, as measurable by the hydrogel having a weight increasing no more than about 40 % upon exposure to a physiological solution for twenty-four hours relative to a weight of the hydrogel at the time of formation and is water-degradation, as measurable by the hydrogel being dissolvable in vitro in an excess of water by degradation of water-degradable groups. |
地址 |
Lexington MA US |